Published in Clin Exp Metastasis on July 05, 2014
Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget (2014) 0.87
Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS One (2016) 0.77
Germline genetics of cancer of unknown primary (CUP) and its specific subtypes. Oncotarget (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 10.29
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev (2005) 4.27
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res (1988) 3.91
Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A (1997) 3.79
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res (2007) 3.51
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 2.58
A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 2.35
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene (2000) 2.27
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res (2011) 2.19
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer (2011) 2.14
Cancer of unknown primary site. Lancet (2012) 2.07
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Ras oncogenes and their downstream targets. Biochim Biophys Acta (2007) 2.00
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.84
FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One (2012) 1.45
Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology (1993) 1.45
KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol (2009) 1.42
The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One (2012) 1.34
Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res (2002) 1.26
Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. Cancer Treat Rev (2013) 1.24
Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer. Clin Cancer Res (2012) 1.21
MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat (2010) 1.13
Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol (2012) 1.09
Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med (2012) 1.08
Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respir Med (2013) 1.07
Molecular analysis of thyroid tumors. Mod Pathol (2011) 1.04
Cancer of unknown primary site: missing primary or missing biology? Oncologist (2007) 1.03
Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomark Res (2013) 0.98
Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion. Carcinogenesis (2012) 0.97
Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark (2010) 0.95
Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care. Virchows Arch (2014) 0.91
HGF/c-Met related activation of β-catenin in hepatoblastoma. J Exp Clin Cancer Res (2011) 0.84
Epigenetic disruption of the WNT/ß-catenin signaling pathway in human cancers. Epigenetics (2009) 0.76
CUP: looking for a missing primary site and its biology. Ann Oncol (2012) 0.75
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer (2006) 2.57
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol (2010) 2.54
Gastric cancer: epidemiology, pathology and treatment. Ann Oncol (2003) 2.53
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol (2010) 2.32
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Rectal metastases from lobular carcinoma of the breast: report of a case and literature review. Ann Oncol (2001) 2.23
Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol (2012) 2.04
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat (2011) 1.87
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.87
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.84
Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol (2004) 1.74
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.73
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol (2010) 1.69
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.68
Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer (2002) 1.68
Telomerase activity in precancerous hepatic nodules. Cancer (1998) 1.59
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst (2010) 1.55
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.52
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. Eur J Cancer (2008) 1.47
A systematic review and meta-analysis of experimental clinical evidence on initial aligning archwires and archwire sequences. Orthod Craniofac Res (2014) 1.42
Health care delivery system. Effects on surgical education: the Mexican panorama. World J Surg (1994) 1.41
Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol (2010) 1.40
A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study. Eur J Cancer (1997) 1.39
Endometrioid carcinoma of the prostate. The diagnostic value of Leu7 and prostatic specific antigen. Br J Urol (1993) 1.38
Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.34
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol (2000) 1.31
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br J Cancer (1994) 1.30
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol (2005) 1.29
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.29
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol (2005) 1.28
A new class of oxidosqualene cyclases directs synthesis of antimicrobial phytoprotectants in monocots. Proc Natl Acad Sci U S A (2001) 1.27
Genetic polymorphism and taxonomic infrastructure of the Pleurotus eryngii species-complex as determined by RAPD analysis, isozyme profiles and ecomorphological characters. Microbiology (2001) 1.25
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer (2003) 1.24
Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat (2010) 1.24
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol (2011) 1.24
Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.23
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer (2006) 1.22
Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol (1994) 1.19
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.18
Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J Clin Endocrinol Metab (1999) 1.17
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer (1994) 1.13
Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Gynecol Oncol (2009) 1.12
Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features. Lung Cancer (2004) 1.12
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol (2005) 1.10
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol (2011) 1.10
Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J Natl Cancer Inst (1989) 1.09
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer (2000) 1.08
Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist (2001) 1.07
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.05
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol (2005) 1.04
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol (2003) 1.04
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol (2014) 1.03
Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol (1998) 1.02
Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time. Eur J Cancer (2003) 1.02
Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol (1999) 1.01
Structural bases of the cytolytic mechanisms of Entamoeba histolytica. J Protozool (1985) 1.01
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol (2005) 1.00
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol (2006) 1.00
Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology (1998) 1.00
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol (2005) 1.00
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer (2008) 0.99
A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin. Anticancer Res (2008) 0.99
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer (2013) 0.99
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol (1994) 0.99
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Ann Oncol (2011) 0.99
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer (2008) 0.97
Cancer and pregnancy: a comprehensive review. Surg Oncol (2011) 0.97
The missing kiss of life: transcriptional activity of the metastasis suppressor gene KiSS1 in early breast cancer. Anticancer Res (2007) 0.96
Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinoma. Histol Histopathol (2004) 0.96
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol (2009) 0.96
Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 0.96
Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Lett (2002) 0.95
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol (2005) 0.95
Primary extranodal non-Hodgkin's lymphoma of the head and neck. Oncology (1992) 0.94
Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res (2000) 0.94
Thyroid disease in Sjögren's syndrome. Arthritis Rheum (1980) 0.94
Maternal race/ethnicity and twinning rates in the United States, 1989-1991. J Reprod Med (2001) 0.94
HLA and Heberden's nodes in Mexican Mestizos. Clin Rheumatol (1985) 0.94